Trifecta Aortic Bioprosthesis: Midterm Results in 1,953 Patients From a Single Center

Kilic, Arman; Sultan, Ibrahim; Navid, Forozan; Aranda‐Michel, Edgar; Chu, Danny; Thoma, Floyd; Gleason, Thomas G.

doi:10.1016/j.athoracsur.2018.10.063

Cited by 54 publications

(45 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For Perimount Magna, reintervention rate was 1% at 10 years, 19 and cumulative incidences of explantation for endocarditis and SVD were 1.2% and 1.0% at 10 years 20 . For Trifecta, three studies have reported the freedom from all‐cause aortic bioprosthesis reintervention at 5 years to be 98.6%, 21 96%, 22 and 84.5% 23 . There is variability between studies and surgical centers, which demonstrates Perimount and Trifecta can have comparable rates of reoperation, but with a slight preponderance in current literature for higher rates of SVD in Trifecta.…”

Section: Discussionmentioning

confidence: 99%

Six‐year follow‐up of aortic valve reoperation rates: Carpentier‐Edwards Perimount versus St. Jude Medical Trifecta

et al. 2020

View full text Add to dashboard Cite

Background: The Carpentier-Edwards Perimount valves have a proven track record in aortic valve replacement: good durability, hemodynamic performance, rates of survival, and low rates of valve-related complications and prosthesis-patient mismatch. The St. Jude Medical Trifecta is a newer valve that has shown comparable early and midterm outcomes. Studies show reoperation rates of Trifecta are comparable with Perimount valves, with a few recent studies bringing into focus early structural valve deterioration (SVD), and increased midterm SVD in younger patients. Given that midterm data for Trifecta is still sparse, we wanted to confirm the early low reoperation rates of Trifecta persist over time compared with Perimount. Methods: The Maritime Heart Centre Database was searched for AVR between 2011 and 2016, inclusive. The primary endpoint of the study was all-cause reoperation rate. Results: In total, 711 Perimount and 453 Trifecta implantations were included. The reoperation hazards were determined for age: 0.96 (0.92-0.99; p = .02), female (vs. male): 0.35 (0.08-1.53; p = .16), smoker (vs. nonsmoker): 2.44 (0.85-7.02; p = .1), and Trifecta (vs. Perimount): 2.68 (0.97-7.39; p = .06). Kaplan-Meier survival analysis in subgroups-age <60, age ≥60, male, female, smoker, and nonsmokershowed Perimount having lower reoperation rates than Trifecta in patients younger than 60 (p = .02) and current smokers (p < .01). Conclusions: The rates of reoperation of Perimount and Trifecta were comparable, with Trifecta showing higher rates in patients younger than 60 years, and current smokers. Continued diligence and further independent reporting of midterm reoperation and SVD rates of the Trifecta, including detailed echocardiographic follow-up, are needed to confirm these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Six‐year follow‐up of aortic valve reoperation rates: Carpentier‐Edwards Perimount versus St. Jude Medical Trifecta

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Also in 2019, Kilic & al. 16 reported three cases out of 1953 implantations of early failed Trifecta due to cusp tear. Our two present cases add up to the aforementioned with an unfavorably early occurrence.…”

Section: Discussionmentioning

confidence: 99%

Early surgical aortic bioprosthesis failure caused by cusp tear: A word of caution

Schaeffer

Berdajs

Reuthebuch

2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…For Perimount Magna, reintervention rate was 1% at 10 years, 19 and cumulative incidences of explantation for endocarditis and SVD were 1.2% and 1.0% at 10 years. 20 For Trifecta, three studies have reported the freedom from all-cause aortic bioprosthesis reintervention at 5 years to be 98.6%, 21 96%, 22 and 84.5%. 23 There is variability between studies and surgical centers, which demonstrates Perimount and Trifecta can have comparable rates of reoperation, but with a slight preponderance in current literature for higher rates of SVD in Trifecta.…”

Section: Discussionmentioning

confidence: 99%

6 Year Follow-up of Aortic Valve Reoperation Rates: Carpentier-Edwards Perimount vs St. Jude Medical Trifecta

Stubeda

Aliter

Gainer

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The Carpentier-Edwards Perimount valves have a proven track record in aortic valve replacement: good durability, hemodynamic performance, rates of survival, and infrequent valve-related complications and PPM. The St. Jude Medical Trifecta is a newer valve that has shown comparable early and midterm outcomes. Studies show reoperation rates of Trifecta are comparable to Perimount valves, with a few recent studies bringing into focus early SVD, and increased midterm SVD in younger patients. Given that midterm data for Trifecta is still sparse, we wanted to confirm the early low reoperation rates of Trifecta persist over time compared to Perimount. Methods The Maritime Heart Centre Database was searched for isolated AVR or AVR+CABG between January 2011 and December 2016. Primary end point of the study was all-cause reoperation rate. Results 711 Perimount and 453 Trifecta implantations were included. The reoperation hazards were determined for age: 0.96 (0.92-0.99, p=0.02), female (vs male): 0.35 (0.08-1.53, p=0.16), smoker (vs non-smoker): 2.44 (0.85-7.02, p=0.1), and Trifecta (vs Perimount): 2.68 (0.97-7.39, p=0.06). Kaplan-Meier survival analysis in subgroups-age < 60, age [?] 60, male, female, smoker, and non-smoker-showed Perimount having lower reoperation rates than Trifecta in patient younger than 60 (p=0.02) and those with smoking history (p<0.01). Conclusions The rates of reoperation of Perimount and Trifecta were comparable, with Trifecta showing higher rates in patients younger than 60 years, and current smokers. Continued diligence and further independent reporting of midterm reoperation and SVD rates of the Trifecta, including detailed echocardiographic follow up, are needed to confirm these findings.

show abstract

Trifecta Aortic Bioprosthesis: Midterm Results in 1,953 Patients From a Single Center

Cited by 54 publications

References 19 publications

Six‐year follow‐up of aortic valve reoperation rates: Carpentier‐Edwards Perimount versus St. Jude Medical Trifecta

Six‐year follow‐up of aortic valve reoperation rates: Carpentier‐Edwards Perimount versus St. Jude Medical Trifecta

Early surgical aortic bioprosthesis failure caused by cusp tear: A word of caution

6 Year Follow-up of Aortic Valve Reoperation Rates: Carpentier-Edwards Perimount vs St. Jude Medical Trifecta

Contact Info

Product

Resources

About